[Long COVID: Is it really myalgic encephalomyelitis? Bibliographic review and considerations].
Espinosa Rodríguez, P, Martínez Aguilar, A, Ripoll Muñoz, M P et al. · Semergen · 2022 · DOI
Quick Summary
This review examines whether long COVID (prolonged symptoms after COVID-19 infection) might actually be myalgic encephalomyelitis (ME/CFS). The authors found striking similarities between long COVID symptoms and the diagnostic criteria used to identify ME/CFS. They recommend that patients with ongoing symptoms after COVID-19 receive blood tests, chest imaging, and long-term medical follow-up to monitor for potential chronic illness development.
Why It Matters
For ME/CFS patients, this study is important because it explores whether a newly recognized post-viral condition (long COVID) might share pathophysiological mechanisms with established ME/CFS, potentially advancing understanding of post-viral chronic illness. The findings support the need for long-term follow-up protocols and suggest that clinical experience gained from COVID-19 research could illuminate ME/CFS pathogenesis and management.
Observed Findings
Symptom overlap exists between long COVID presentations and ICC diagnostic criteria for ME/CFS, including post-exertional malaise-like symptoms, fatigue, and neurological manifestations.
Diagnostic workup for persistent post-COVID symptoms should include blood tests, pulse oximetry, chest imaging, and thoracic ultrasound.
Both long COVID and ME/CFS management currently focuses on symptomatic treatment rather than disease-modifying interventions.
The temporality and definitions of long COVID remain heterogeneous across different case definitions and populations studied.
Inferred Conclusions
Some patients with long COVID may develop chronic illness meeting ME/CFS criteria, warranting extended clinical surveillance.
The symptomatic similarities between long COVID and ME/CFS suggest shared post-viral pathophysiological mechanisms may be operating.
Primary care providers should apply ME/CFS diagnostic frameworks when evaluating patients with prolonged post-COVID symptoms.
Long-term follow-up studies are needed to determine the natural history and eventual outcomes of long COVID in affected populations.
Remaining Questions
What proportion of long COVID patients actually meet full ICC criteria for ME/CFS diagnosis at different time points post-infection?
What This Study Does Not Prove
This review does not establish that long COVID is definitively ME/CFS—it identifies similarities but cannot prove causation or that they are identical conditions. The study presents no new empirical data, diagnostic accuracy statistics, or prevalence figures, so it does not quantify how often long COVID actually develops into ME/CFS. It also does not address potential differences in etiology, immune markers, or treatment response between the two conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Are there distinguishing immunological, metabolic, or neurophysiological markers that differentiate long COVID from primary ME/CFS or identify which post-COVID patients will develop ME/CFS?
Do long COVID and ME/CFS respond differently to specific therapeutic interventions, and what does this reveal about their underlying mechanisms?
What are the 1, 2, and 5-year natural history trajectories for patients with long COVID, and what factors predict progression to chronic disabling illness?